Contineum Therapeutics Inc (CTNM)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Fiscal Year End Date: 12/31
(Values in U.S. thousands)
| 12-2025 | 12-2024 | 12-2023 | 12-2022 | |
| Assets | ||||
| Current Assets | ||||
| Cash & Cash Equivalents | 75,603 | 21,943 | 15,526 | 5,569 |
| Marketable Securities | 187,293 | 182,817 | 109,664 | 41,670 |
| TOTAL | $267,917 | $206,388 | $127,706 | $48,392 |
| Non-Current Assets | ||||
| PPE Net | 830 | 989 | 678 | 431 |
| Other Non-Current Assets | 7,895 | 5,470 | 2,002 | 1,813 |
| TOTAL | $8,725 | $6,459 | $2,680 | $2,244 |
| Total Assets | $276,642 | $212,847 | $130,386 | $50,636 |
| Liabilities | ||||
| Current Liabilities | ||||
| Short Term Debt | N/A | N/A | 464 | 3,948 |
| Accounts payable and accrued liabilities | 1,016 | 1,811 | 635 | 430 |
| Accrued Expenses | 6,387 | 6,711 | 4,385 | 2,062 |
| TOTAL | $9,744 | $9,974 | $5,484 | $7,550 |
| Non-Current Liabilities | ||||
| Other Non-Current Liabilities | 5,909 | 4,807 | 192,838 | 136,298 |
| TOTAL | $5,909 | $4,807 | $192,838 | $136,298 |
| Total Liabilities | $15,653 | $14,781 | $198,322 | $143,848 |
| Shareholders' Equity | ||||
| Shares Outstanding, K | 37,336 | 25,872 | N/A | N/A |
| Common Shares | 37 | 26 | 2 | 2 |
| Retained earnings | -177,380 | -117,402 | -75,144 | -97,864 |
| Other shareholders' equity | 260 | 71 | 108 | -76 |
| TOTAL | $260,989 | $198,066 | $-67,936 | $-93,212 |
| Total Liabilities And Equity | $276,642 | $212,847 | $130,386 | $50,636 |